Retatrutide has become one of the most searched weight loss drugs in the country, and it is showing up on med spa menus under the nickname “GLP-3.” The regulatory picture is much simpler than the marketing suggests: retatrutide is not FDA approved, and the FDA has said compounded versions do not qualify for the exemptions that normally allow compounding. Here is what that means for clinics, med spas, and the physicians who oversee them.
Where retatrutide stands today
Retatrutide is an investigational drug that targets three hormone pathways (GIP, GLP-1, and glucagon). Early trial results have been striking, which is a big reason demand has surged. But it is still in clinical development. There is no FDA-approved retatrutide product for any indication, and long-term safety data is still being collected.
“GLP-3” is a marketing nickname, not a regulatory category. It does not create any special legal pathway, and it should not appear as a service on a clinic menu.
What the FDA has said about compounding
Pharmacies can compound certain drugs under two sections of the federal Food, Drug, and Cosmetic Act. Section 503A covers traditional compounding pharmacies. Section 503B covers outsourcing facilities. The FDA has stated that compounded retatrutide products do not qualify for either exemption. In plain terms, the substance is not the subject of a USP monograph, is not a component of an FDA-approved drug, and is not on the 503A or 503B bulk substances lists. It is also not on the FDA drug shortage list.
The FDA has also warned companies that sell retatrutide labeled “for research use only” or “not for human consumption.” Those labels do not change the fact that the products are being marketed with dosing instructions to consumers, and the agency has treated them as unapproved drugs.
Why this matters for med spas and clinics
If a clinic prescribes, dispenses, administers, or advertises retatrutide, the risk does not stop with the pharmacy. It lands on the clinic, the prescriber, and the supervising physician. The main exposure points are:
- Regulatory exposure. Offering an unapproved drug can draw attention from the FDA and from state medical and pharmacy boards.
- Marketing exposure. Advertising an unapproved drug, or making weight loss claims about it, creates separate problems under FDA and FTC rules.
- Liability and insurance. Malpractice carriers may not cover treatment with unapproved drugs. Ask your carrier directly and get the answer in writing.
- Supply chain risk. “Research” peptides come with unknown purity, dosing, and sterility, and there is no quality oversight behind them.
What a medical director should do
A medical director’s job is to protect the clinic’s patients and its license footprint. For retatrutide, that means keeping it off the treatment menu, out of protocols, and out of advertising until there is an approved product and a lawful way to prescribe it. It also means auditing what is already in the clinic: websites, social posts, intake forms, and what front desk staff say when patients ask.
US Medical Directors does not provide oversight or clearance for retatrutide. Clinics that want to keep growing a weight management line can build durable programs around FDA-approved medications and strong lifestyle and monitoring support, which is a better long-term foundation anyway.
Practical checklist for your clinic
- Remove retatrutide and “GLP-3” language from your website, menus, ads, and social profiles.
- Do not purchase “research use only” peptides for patient use.
- Give staff a short, approved answer for patients who ask about it.
- Review your weight loss protocols with your medical director so every drug on the menu is FDA approved or lawfully compounded.
- Check your state board’s current guidance and your malpractice policy.
What could change
If retatrutide is eventually approved, the situation changes for the approved product. Approval would create a legitimate prescribing pathway, but it would not automatically make compounded copies lawful. Rules in this area have shifted quickly for other GLP-1 drugs, so confirm the current status before making any decisions.
This article is for general education and is not legal or medical advice. Regulations change, so confirm current requirements with your attorney and state board.
